/stocks — the workspaceLOADING
All KALA SEC filings, by type → · Earnings date & implied move · Search inside filings
KALA BIO, Inc. (KALA) is a pharmaceutical preparations company. Piotroski F-Score 3/8. Fundamentals from SEC filings; prices are end-of-day.
What’s behind KALA’s latest move — the size, how unusual the volume is, and the catalyst on the tape, explained and cited to the source.
End-of-day bars · delayed, not real-time · data: Databento · studies computed in your browser from these barsCharting by TradingView Lightweight Charts™
FY ending 2017-12-31 vs 2016-12-31. original 1968 formula; calibrated on manufacturers, read financials/REITs with care
Estimates, not targets. The DCF treats free cash flow as cash flow to equity and divides by shares (the common retail shortcut — it skips net debt and a full WACC), so it’s a sanity-check, not a valuation opinion. All inputs are from KALA’s SEC filings; change any assumption above and the numbers update live. Educational only — not investment advice.
A plain-English read on KALA plus an auto-SWOT — built from KALA's SEC filings and market data, every point cited, nothing invented. Educational, not investment advice.
Four AI analysts — a bull, a bear, a risk manager, and a PM — debate KALA using only the SEC-filing and market facts below. Every point cites its evidence; nothing is invented. This is educational research, not investment advice.
Educational only — not financial advice. Data from SEC EDGAR public filings; no live market data is shown. Figures reflect the company's own reported XBRL facts and may lag.
XBRL company facts, SEC EDGAR. TTM = last four reported quarters. Valuation ratios arrive with a price source — we don't fake quotes.
↓ Download the fiscal-year statement table (XLSX) · revenue, income, EPS, cash flow, balance sheet · from SEC XBRL, dated
No lawmaker has disclosed a trade in KALA under the STOCK Act.
Projected from KALA's own SEC 8-K filing history — the year-over-year reporting pattern (about 47% land the exact day, about 91% within a week, measured across 4,713 past reports). No analyst estimates and nothing invented, and every confirmed date links to the source it came from, so you can check it yourself. It upgrades the momentKALA files or announces.
KALA has sold off after 3 of its last 4 earnings reports.
Each figure is one earnings reaction — how much KALA moved from the closing price the day before a report to the close the day after. Based on its last 4 reports.
Earnings reactions have been moderate.
KALA has traded lower after most recent earnings releases.
A more typical earnings reaction has been approximately ±5.7%.
Realized close-to-close history only — no options-implied move, no analyst estimates.
| Reported | Close-to-close |
|---|---|
| 2025-08-08 | +0.6% |
| 2025-05-14 | -7.5% |
| 2025-03-31 | -5.3% |
| 2024-11-12 | -6.1% |
Earnings dates are the company's 8-K Item 2.02 filings (SEC). Reactions from Databento EOD.
No tracked institution reported a position in KALA in the latest 13F round.
No open-market Form 4 buys or sells reported for KALA in the last ~6 months.
Head office: Arlington, Massachusetts, United States · the company’s charter and its head office are in different states.
Source: the cover page of KALA BIO, Inc.’s 10-Q filed 2026-08-19, on EDGAR. Filings checked 2026-10-15. Incorporation is where the company’s charter was filed. It is not where the business operates or earns, which no filing cover states. How this works